REVENUES (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
|---|
| REVENUES |
|
| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
38,585 |
|
$ |
26,977 |
|
$ |
105,239 |
|
|
76,022 |
Discounts and allowances |
|
|
(11,456) |
|
|
(7,789) |
|
|
(30,484) |
|
|
(22,087) |
Total product sales, net |
|
|
27,129 |
|
|
19,188 |
|
|
74,755 |
|
|
53,935 |
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
|
|
|
License revenues |
|
|
— |
|
|
— |
|
|
— |
|
|
2,545 |
Development milestones |
|
|
75 |
|
|
— |
|
|
75 |
|
|
5,000 |
Royalty, delivery of drug supplies and others |
|
|
930 |
|
|
722 |
|
|
5,260 |
|
|
4,984 |
Total revenues from collaborations |
|
|
1,005 |
|
|
722 |
|
|
5,335 |
|
|
12,529 |
Government contract |
|
|
— |
|
|
2,500 |
|
|
1,000 |
|
|
2,500 |
Total revenues |
|
$ |
28,134 |
|
$ |
22,410 |
|
$ |
81,090 |
|
$ |
68,964 |
|
| Schedule of product revenue allowance and reserve categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2023 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
Provision related to current period sales |
|
|
23,150 |
|
|
5,932 |
|
|
623 |
|
|
29,705 |
Credit or payments made during the period |
|
|
(21,504) |
|
|
(5,631) |
|
|
(172) |
|
|
(27,307) |
Balance as of September 30, 2023 |
|
$ |
7,859 |
|
$ |
2,937 |
|
$ |
3,747 |
|
$ |
14,543 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2022 |
|
$ |
3,404 |
|
$ |
2,494 |
|
$ |
2,017 |
|
$ |
7,915 |
Provision related to current period sales |
|
|
14,475 |
|
|
4,130 |
|
|
1,045 |
|
|
19,650 |
Credit or payments made during the period |
|
|
(11,920) |
|
|
(4,257) |
|
|
(199) |
|
|
(16,376) |
Balance as of September 30, 2022 |
|
$ |
5,959 |
|
$ |
2,367 |
|
$ |
2,863 |
|
$ |
11,189 |
|
| Schedule of revenues from product sales disaggregated by customers |
The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
2023 |
|
2022 |
|
|
2023 |
|
2022 |
McKesson Specialty Care Distribution Corporation |
|
|
49% |
|
|
44% |
|
|
|
46% |
|
|
38% |
Cardinal Healthcare |
|
|
28% |
|
|
27% |
|
|
|
27% |
|
|
22% |
ASD Healthcare and Oncology Supply |
|
|
18% |
|
|
25% |
|
|
|
20% |
|
|
21% |
Kissei |
|
|
* |
|
|
* |
|
|
|
* |
|
|
11% |
|